GlassScriptPhysician profile
Antine Elaine Stenbit
NPI 1659475432
$7,199.48
in general payments reported to CMS, 2019-2025
33 companies · $1,304 in 2025
The $1,304 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $88.79 · 2021: $148 · 2022: $246 · 2023: $180 · 2024: $4,575 · 2025: $1,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,020 · Food and Beverage: $2,981 · Travel and Lodging: $57.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,020.00 |
| Food and Beverage | $2,981.01 |
| Travel and Lodging | $57.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,577.42 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $560.35 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Regeneron Healthcare Solutions, INC. | $448.53 | 2023-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $337.90 | 2019-2025 | Opsumit |
| Glaxosmithkline, LLC. | $216.21 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| United Therapeutics Corporation | $169.44 | 2019-2024 | Tyvaso |
| Phathom Pharmaceuticals, INC. | $166.29 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $147.44 | 2019 | |
| Abiomed | $145.71 | 2022 | |
| Amgen INC. | $142.39 | 2024-2025 | Tezspire |
| Verona Pharma, INC. | $137.39 | 2025 | Ohtuvayre |
| Baxter Healthcare | $134.52 | 2022-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Sunovion Pharmaceuticals INC. | $129.78 | 2019-2020 | |
| Grifols USA, LLC | $127.49 | 2019-2025 | Xembify |
| Advanced Respiratory, INC | $127.00 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $102.23 | 2019-2025 | Brinsupri, Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.93 | 2024 | Ofev |
| Pharming Healthcare, INC. | $58.89 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.86 | 2025 | Glassia |
| Lundbeck LLC | $54.72 | 2025 | Vyepti |
| Merck Sharp & Dohme LLC | $44.60 | 2019 | |
| Ani Pharmaceuticals, INC. | $38.41 | 2025 | Purified Cortrophin Gel |
| Aerin Medical INC. | $34.94 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.50 | 2024 | |
| Abbvie INC. | $19.61 | 2020 | |
| Tactile Systems Technology INC | $19.58 | 2025 | Nimbl, Flexitouch Plus |
| Inspire Medical Systems, INC. | $18.41 | 2025 | Inspire |
| Vapotherm INC | $16.58 | 2022 | |
| Circassia INC. | $14.84 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.79 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.43 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $14.30 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antine Stenbit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.